By Kamal Choudhury (Reuters) -Vaccine maker Novavax's shares plunged nearly 20% at market close on Thursday, after Health and ...

Five years ago, volunteers rolled up their sleeves in the first clinical trial of a vaccine against COVID-19, as the new pandemic surged around them. By a year later, 66 million American adults had ...

A passion for learning took her from apartheid South Africa to a beer brewery to becoming a healthcare consultant, all before ...

These five well-known dividend stocks were beaten down in the recent selling but will remain attractive long after the tariff ...

Concern is growing among public health experts that anti-vaccine sentiments within federal and state governments may derail ...

Pfizer’s blockbuster COVID era has officially left the chat, but the pharmaceutical giant is scripting a bold new chapter.

Officials say the Army has reenlisted more than 23 soldiers who were discharged for refusing the COVID-19 vaccine.

Large-cap pharmaceutical stocks like these may now be positioned to outperform as the impact of tariffs begins to take hold.

From stock decline to Hold rating, explore their growth strategy, client focus, and potential gains. Click for my MRVI update ...

Thousands of people were laid off Tuesday at the United States' top health agencies. Here are what positions and efforts were ...

The U.S. Food and Drug Administration (FDA) has delayed the full approval of Novavax’s COVID-19 vaccine.  The decision had ...